Bridgefront Capital’s BridgeBio Pharma BBIO Stock Holding History

Bridgefront Capital’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-13,983	Closed	-$604K	–	587
2025 Q2	$604K	Buy	+13,983	New	+$509K	0.16%	232
2022 Q4	–	Sell	-12,256	Closed	-$122K	–	368
2022 Q3	$122K	Buy	+12,256	New	+$127K	0.13%	265
2022 Q1	–	Sell	-14,689	Closed	-$245K	–	272
2021 Q4	$245K	Buy	+14,689	New	+$621K	0.24%	190

Other funds holding BBIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bridgefront Capital's BBIO Position: Q3 2025 in Review

Bridgefront Capital sold out of BridgeBio Pharma (BBIO) in Q3 2025, closing a stake of 13,983 shares — an estimated $604K sold.

Bridgefront Capital first reported a position in BBIO in Q4 2021 and held it in 3 quarters. The position peaked at $604K in Q2 2025. 392 funds tracked by Wall St. Rank hold BBIO as of Q3 2025.

Bridgefront Capital reported no remaining BridgeBio Pharma position as of Q3 2025 after selling out during the quarter.
Bridgefront Capital sold 13,983 BridgeBio Pharma shares in Q3 2025, an estimated $604K.
Bridgefront Capital first reported a position in BridgeBio Pharma in Q4 2021 and held it in 3 quarters.
Bridgefront Capital's BridgeBio Pharma position peaked at $604K in Q2 2025.
392 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2025.

Based on Bridgefront Capital's 13F filing for Q3 2025, filed 14 Nov 2025.